Phase 2 Refractory Peripheral T-Cell Lymphoma Clinical Trials
8 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–8 of 8 trials
Recruiting
Phase 1Phase 2
Study to Evaluate Efficacy and Safety of HH2853 in Relapsed/Refractory Peripheral T-cell Lymphoma
Relapsed/Refractory Peripheral T-Cell Lymphoma (R/R PTCL)
Haihe Biopharma Co., Ltd.100 enrolled1 locationNCT06909877
Recruiting
Phase 2
Phase II Clinical Trial of Drug Combinations Guided by Ex-vivo Testing in Patients With Relapsed/Refractory T-cell Lymphoma (COMBINEX-T)
Relapsed/Refractory Peripheral T-cell Lymphoma (RR PTCL)
National University Hospital Singapore36 enrolled1 locationACTRN12626000088347
Recruiting
Phase 2
Pembrolizumab and Olaparib Treatment for Relapsed or Refractory Peripheral T-Cell Lymphoma
Relapsed Peripheral T-Cell LymphomaRefractory Peripheral T-Cell Lymphoma
National Cancer Centre, Singapore24 enrolled1 locationNCT06160843
Recruiting
Phase 2
Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL)
Relapsed or Refractory Peripheral T-cell Lymphoma
Great Novel Therapeutics Biotech & Medicals Corporation33 enrolled5 locationsNCT05833724
Recruiting
Phase 1Phase 2
A Phase I/II Study of Golidocitinib Combined with Pomalidomide in R/R PTCL
Relapsed/Refractory Peripheral T-Cell Lymphoma (R/R PTCL)
Sun Yat-sen University33 enrolled1 locationNCT06855823
Recruiting
Phase 1Phase 2
A Study of GFH009 Monotherapy in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Genfleet Therapeutics (Shanghai) Inc.95 enrolled1 locationNCT05934513
Recruiting
Phase 1Phase 2
Azacytidine Plus CAOLD Regimen in Relapsed/Refractory Peripheral T-Cell Lymphomas
Relapsed Peripheral T-Cell LymphomasRefractory Peripheral T-Cell Lymphomas
Navy General Hospital, Beijing52 enrolled1 locationNCT06176027
Terminated
Phase 2
Trial of KPT-330 in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) and Cutaneous T cell Lymphoma (CTCL)
Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)Relapsed or Refractory Cutaneous T cell Lymphoma (CTCL)
Karyopharm Therapeutics Inc.30 enrolled4 locationsACTRN12614001328662